Read More

Portage Biotech Acquires Tarus Therapeutics In Exchange For 2,425,999 PRTG Shares Along With Assumption Of $3M In Liabilities; Additionally, Payments Of Up To $32M Would Be Triggered Upon Achievement Of Future Milestones

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at

PRTG